The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)

August 2020 | Volume 19 | Issue 8 | Original Article | 703 | Copyright © August 2020


Published online July 22, 2020

M. Alan Menter MDa, Nehal N. Mehta MD MSCE FAHAb, Mark G. Lebwohl MDc, Alice B. Gottlieb MD PhDd, Alan M. Mendelsohn MDe, Stephen J. Rozzo PhDe, Craig Leonardi MDf

aDivision of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX BNational Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD cDepartment of Dermatology, Mount Sinai Hospital, New York, NY dDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY eSun Pharmaceutical Industries, Inc., Princeton, NJ fCentral Dermatology and Saint Louis University School of Medicine, St. Louis, MO

Mean changes in cardiometabolic risk factors LDL-C, TC, body weight, and DBP were similar in patients with and without MetS receiving tildrakizumab 100 mg (Figure 1A). Both FG and TG were numerically decreased relative to baseline in patients with MetS but not in patients without MetS; patients with MetS had numerically larger decreases in SBP from baseline relative to patients without MetS at week 64/52 (Figure 1A). Mean percent changes from baseline (95% CI) at week 64/52 for patients with MetS relative to patients without MetS were –1.4 (–6.0, 3.2) vs 4.7 (2.6, 6.8) for FG, 4.4 (–5.0, 13.8) vs 16.6 (10.6, 22.6) for TG, and –1.5 (–3.6, 0.6) vs –0.3 (–1.5, 0.9), for SBP.

Patients with MetS receiving 200 mg tildrakizumab had similar mean changes from baseline in LDL-C, HDL-C, TC, TG, and body weight relative to patients without MetS (Figure 1B). Patients with MetS had numerically larger mean decreases in SBP and DBP and a numerically larger mean increase in FG from baseline relative to patients without MetS at week 64/52 (Figure 1B).